Certara (CERT) Stock
Drug discovery software and consulting for pharmaceutical companies. Here's the price, business snapshot, and what's worth knowing about Certara in July 2026.
Certara Inc (CERT) provides software and consulting services that use pharmacological modelling and simulation to support drug discovery and development. Its platforms help pharmaceutical and biotech companies design trials, predict dosing and accelerate regulatory submissions. With a market capitalisation of about $1.97 billion, Certara combines recurring subscription revenue from software with professional services and royalties. Investors often watch its revenue growth, gross margins and progress integrating acquisitions that broaden its modelling capabilities. Opportunities centre on the wider adoption of model-informed drug development and rising R&D spend, but there are risks: exposure to pharmaceutical budgets, competitive technologies, and execution on product development and integration. Financial performance can be variable and past trends don’t guarantee future returns. This summary is educational only and not personal investment advice; investors should assess suitability for their own circumstances and consider professional advice where appropriate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Certara's stock, expecting it to reach a higher value soon.
Financial Health
Certara is showing strong revenue and cash flow, indicating good financial performance and stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AUTOMATIC DATA PROCESSING INC
Provides business process outsourcing and technology services.
AIRBNB INC
Airbnb is a hospitality company that provides a platform for users to list, discover, and book accommodations and experiences around the world.
ADOBE INC
Develops software and cloud-based solutions for digital media and digital marketing.
Baskets Featuring CERT
Clinical Trial Tech: Growth vs Competition Risks
Thermo Fisher's multi-billion dollar acquisition of Clario, a clinical trial data company, signals a major industry shift towards digital solutions. This creates a compelling investment case for companies specializing in the software and data analytics that power modern drug development.
Published: 29 October 2025
Explore BasketRegTech Stocks: What's Next After Bank Penalties
A record fine against a major Australian bank for serious misconduct highlights systemic failures in the financial sector. This event is expected to drive significant investment in governance, risk, and compliance (GRC) solutions as institutions race to meet stricter regulatory standards.
Published: 15 September 2025
Explore BasketTrust Brokers
In today's uncertain world, these carefully selected companies profit by providing essential security, validation, and certification services. They sell trust itself—a non-discretionary commodity that commands premium pricing and ensures reliable demand regardless of economic conditions.
Published: 17 June 2025
Explore BasketWhy You’ll Want to Watch This Stock
Model‑Informed Development
Certara’s modelling platforms can reduce trial time and cost, a theme investors may find interesting — though outcomes can vary with execution and adoption.
Recurring Revenue Mix
Subscription software plus services offer recurring revenue potential, but margins depend on scale, pricing and successful integration of acquisitions.
Sector Tailwinds
Growing R&D spend and regulatory interest in simulation support long‑term demand, yet sensitivity to pharma budgets and competition adds uncertainty.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
